ClinicalTrials.gg
Not yet recruitingNCT07011693SMART-IUpdated Jun 10, 2025

Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression(SMART-I)

A Phase 4 interventional study of Sertraline and Agomelatine in Major Depressive Disorder (MDD), sponsored by Xinyu Zhou. Not yet recruiting at 1 site in China. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-06-10.

Sponsored by Xinyu Zhou · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies testing sertraline in Depressive Disorder, Major — 6 open to participants now, 7 under way, none of them phase 3. Sertraline · Depressive Disorder, Major.

Planned enrollment
4th of 44
400 · median 78
Started
2025
with 3 others
Phase 4
16 of 44
3 open now
Registered
41st of 44
by date

Among the 44 studies testing sertraline in Depressive Disorder, Major, this one is the 4th largest by planned enrollment, is one of 4 that started in 2025, is one of 16 in phase 4, and was the 41st registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

6 of the 44 studies testing sertraline in Depressive Disorder, Major are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About sertraline

Sertraline: first FDA approval 1991 (ZOLOFT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing sertraline in Depressive Disorder, Major, or all of them as a file.
02

Study summary

This project aims to investigate the effectiveness of existing common antidepressants in adolescents with MDD who did not respond to their first treatment.

Read the detailed description

This project aims to investigate the effectiveness of existing common antidepressants in adolescents with MDD who did not respond to their first treatment. Adolescents ages 12 to 17, currently taking a prescribed selective serotonin reuptake inhibitor (SSRI) at least 8 weeks and still experiencing depression, participate in a 8-week randomized treatment study that includes one of three conditions: (1) switching to sertraline , (2) switching to duloxetine , (3) augmentation of their original SSRI with aripiprazole.

03

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • adolescent
  • SSRI
  • depression
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 12-17;
  2. As assessed by K-SADS-PL, it meets the criteria for MDD;
  3. CDRS-R≥45;
  4. CGI-S≥4;
  5. Failed to respond to an initial SSRI trial: the trial at least 8 weeks, with the last of which were at a dosage of at least 40 mg per day of fluoxetine or its equivalent.

Exclusion criteria

Exclusion Criteria:

  1. Current or lifetime diagnosis of bipolar disorder, schizophrenia, autism, attention-deficit/hyperactivity disorder or obsessive-compulsive disorder or psychosis not otherwise specified;
  2. MDD with psychotic symptoms;
  3. YMRS>13;
  4. Current or lifetime diagnosis of serious neurologic diseases such as epilepsy, brain trauma or other serious physical illnesses;
  5. Failure to respond adequately to two or more antidepressant treatment trials of recommended dose and length (at least 8 weeks, with the last 4 of which were at a dosage of at least 40 mg per day of fluoxetine or its equivalent);
  6. History of clear-cut intolerability of, or lack of effect with, an adequate trial of sertraline, agomelatine, or aripiprazole;
  7. Current depressive episode with clear suicidal plans or behaviors;
  8. Received modified electroconvulsive therapy within 3 months;
  9. Taking any medicine that contraindicates in combination with or interferes with the efficacy of the treatment;
  10. Substance abuse or dependence;
  11. Female patients with pregnancy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Group1-sertraline

    dosage form: po dosage:25-200mg frequency:qd duration: patients will be given sertraline as a switching treatment to SSRI.

    Drug: Sertraline

  • Experimental
    Group 2-agomelatine

    dosage form: po dosage:25-50mg frequency:qd duration: patients will be given agomelatine as a switching treatment to SSRI.

    Drug: Agomelatine

  • Experimental
    Group 3-aripiprazole with original SSRI

    dosage form: po dosage: 1.25-15mg frequency:qn duration: patientswill be given aripiprazole as an add-on treatment to original SSRI.

    Drug: Aripiprazole

Interventions

  • Commonly used oral antipsychotics intervention therapy.

  • Commonly used oral antipsychotics intervention therapy.

  • Commonly used oral antipsychotics intervention therapy.

06

What researchers measure

Primary outcomes

  1. response rate of Children's Depression Rating Scale (CDRS-R) scores

    The primary outcomes are the treatment response rate (reduction rate of CDRS-R≥50%). The CDRS-R is a scale consisting of 17 items that are evaluated by clinicians to assess the intensity of depressive symptoms in adolescents, with items scored on scales of 1 to 5 or 1 to 7, resulting in a possible total score range of 17 to 113,higher scores mean a worse outcome.

    Time frame: Baseline of treatment period, 4 weeks, 8 weeks

Secondary outcomes

  1. Change in Baker Depression Scale(BDI-II) scores from baseline

    Change in BDI-II scores from baseline,The BDI is a self-report rating scale containing 21 items. Based on the BDI scores, depression can be classified into six levels: normal (1-10), mild mood disorder (11-16), borderline clinical depression (17-20), moderate depression (21-30), severe depression (31-40), and extreme depression (over 40).Higher scores mean a worse outcome.

    Time frame: Baseline of treatment period, 4 weeks, 8 weeks

  2. Change in The Screen for Child Anxiety-Related Emotional Disorders (SCARED) scores from baseline

    The SCARED is employed to evaluate child anxiety symptoms. Each question is rated from 0 to 2, with 0 denoting "not true or hardly ever true," 1 denoting "somewhat true or sometimes true", and 2 denoting "extremely true or often true". The maximum total score is 63. Higher scores mean a better or worse outcome.

    Time frame: Baseline of treatment period, 4 weeks,8 weeks

  3. Change in CGI-S (Clinical Global Impressions-Severity Scales) scores from baseline

    Improvement in overall clinical impression severity( 7-point scale, with 1 being normal and 7 being among the most severely damaged

    Time frame: Baseline of treatment period, 4 weeks, 8 weeks,

  4. Adverse Event (AE) or Serious Adverse Event (SAE)

    Change in suicide risk from baseline on the C-SSRS (Columbia Suicide Severity Rating Scale), Adverse Event (AE) or Serious Adverse Event (SAE)

    Time frame: Baseline of treatment period, 1 month, 2 months,

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Jun 2027, 24 months later.

Of 79 non-industry phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's planned 24 months is below that.

Counting every sponsor, half of 98 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2025
First posted
Jun 10, 2025
StartEst.
Jun 20, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2027
Last update
Jun 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07011693
Lead sponsor
Xinyu Zhou
Responsible party
Xinyu Zhou (Professer, First Affiliated Hospital of Chongqing Medical University) — Sponsor-investigator
First posted
Jun 10, 2025
Start date
Jun 20, 2025 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 10, 2025

Study contacts

Xinyu Zhou
Contact
zhouxinyu@cqmu.edu.cn
2912-89012912

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sertraline · Agomelatine · Aripiprazole

Start the discussion